ProQR Therapeutics BV Net Income
| PRQR Stock | USD 1.44 0.04 2.70% |
As of the 11th of February 2026, ProQR Therapeutics holds the Variance of 19.24, risk adjusted performance of (0.11), and Coefficient Of Variation of (706.86). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProQR Therapeutics, as well as the relationship between them. Please check ProQR Therapeutics market risk adjusted performance and treynor ratio to decide if ProQR Therapeutics is priced some-what accurately, providing market reflects its current price of 1.44 per share. Please also confirm ProQR Therapeutics jensen alpha, which is currently at (0.68) to check out the company can sustain itself at a future point.
ProQR Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.6419 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -25 M | -26.2 M | |
| Net Loss | -58.6 M | -61.5 M | |
| Net Loss | -25 M | -26.2 M | |
| Net Loss | (0.31) | (0.32) | |
| Net Income Per E B T | 0.89 | 0.80 |
ProQR | Net Income | Build AI portfolio with ProQR Stock |
Evaluating ProQR Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into ProQR Therapeutics BV's fundamental strength.
Latest ProQR Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of ProQR Therapeutics BV over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ProQR Therapeutics financial statement analysis. It represents the amount of money remaining after all of ProQR Therapeutics BV operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ProQR Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProQR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (27.76 M) | 10 Years Trend |
|
Net Income |
| Timeline |
ProQR Net Income Regression Statistics
| Arithmetic Mean | (29,481,455) | |
| Coefficient Of Variation | (69.64) | |
| Mean Deviation | 16,675,155 | |
| Median | (27,763,000) | |
| Standard Deviation | 20,531,139 | |
| Sample Variance | 421.5T | |
| Range | 61.2M | |
| R-Value | (0.58) | |
| Mean Square Error | 297.7T | |
| R-Squared | 0.34 | |
| Significance | 0.01 | |
| Slope | (2,363,567) | |
| Total Sum of Squares | 6744.4T |
ProQR Net Income History
Other Fundumenentals of ProQR Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ProQR Therapeutics Net Income component correlations
ProQR Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ProQR Therapeutics is extremely important. It helps to project a fair market value of ProQR Stock properly, considering its historical fundamentals such as Net Income. Since ProQR Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ProQR Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ProQR Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does ProQR have expansion opportunities? Factors like these will boost the valuation of ProQR Therapeutics. Anticipated expansion of ProQR directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating ProQR Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.48) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
ProQR Therapeutics's market price often diverges from its book value, the accounting figure shown on ProQR's balance sheet. Smart investors calculate ProQR Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since ProQR Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ProQR Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProQR Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ProQR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ProQR Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ProQR Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ProQR Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in ProQR Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding ProQR Therapeutics BV or generate 0.0% return on investment in ProQR Therapeutics over 90 days. ProQR Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics... More
ProQR Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ProQR Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ProQR Therapeutics BV upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 25.48 | |||
| Value At Risk | (7.35) | |||
| Potential Upside | 5.83 |
ProQR Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProQR Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ProQR Therapeutics' standard deviation. In reality, there are many statistical measures that can use ProQR Therapeutics historical prices to predict the future ProQR Therapeutics' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (1.08) | |||
| Treynor Ratio | (1.16) |
ProQR Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (1.15) | |||
| Mean Deviation | 3.31 | |||
| Coefficient Of Variation | (706.86) | |||
| Standard Deviation | 4.39 | |||
| Variance | 19.24 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.68) | |||
| Total Risk Alpha | (1.08) | |||
| Treynor Ratio | (1.16) | |||
| Maximum Drawdown | 25.48 | |||
| Value At Risk | (7.35) | |||
| Potential Upside | 5.83 | |||
| Skewness | (0.36) | |||
| Kurtosis | 1.48 |
ProQR Therapeutics Backtested Returns
ProQR Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.13, which implies the firm had a -0.13 % return per unit of risk over the last 3 months. ProQR Therapeutics exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check ProQR Therapeutics' Coefficient Of Variation of (706.86), variance of 19.24, and Risk Adjusted Performance of (0.11) to confirm the risk estimate we provide. The company holds a Beta of 0.54, which implies possible diversification benefits within a given portfolio. As returns on the market increase, ProQR Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding ProQR Therapeutics is expected to be smaller as well. At this point, ProQR Therapeutics has a negative expected return of -0.56%. Please make sure to check ProQR Therapeutics' jensen alpha and rate of daily change , to decide if ProQR Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.23 |
Weak reverse predictability
ProQR Therapeutics BV has weak reverse predictability. Overlapping area represents the amount of predictability between ProQR Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ProQR Therapeutics price movement. The serial correlation of -0.23 indicates that over 23.0% of current ProQR Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.23 | |
| Spearman Rank Test | -0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ProQR Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ProQR Therapeutics BV reported net income of (27.76 Million). This is 108.13% lower than that of the Biotechnology sector and 139.64% lower than that of the Health Care industry. The net income for all United States stocks is 104.86% higher than that of the company.
ProQR Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProQR Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProQR Therapeutics could also be used in its relative valuation, which is a method of valuing ProQR Therapeutics by comparing valuation metrics of similar companies.ProQR Therapeutics is currently under evaluation in net income category among its peers.
ProQR Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ProQR Therapeutics from analyzing ProQR Therapeutics' financial statements. These drivers represent accounts that assess ProQR Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ProQR Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 452.1M | 247.6M | 145.1M | 209.0M | 240.3M | 280.2M | |
| Enterprise Value | 324.9M | 174.7M | 35.5M | 76.8M | 88.3M | 83.9M |
ProQR Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in ProQR Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ProQR Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ProQR Therapeutics' value.| Shares | Millennium Management Llc | 2025-06-30 | 1.3 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2025-06-30 | 1.2 M | Ubs Group Ag | 2025-06-30 | 1.1 M | M28 Capital Management Lp | 2025-06-30 | 1 M | Ikarian Capital, Llc | 2025-06-30 | 868.1 K | Point72 Asset Management, L.p. | 2025-06-30 | 750 K | Macquarie Group Ltd | 2025-06-30 | 620 K | Walleye Trading Advisors, Llc | 2025-06-30 | 532 K | Monaco Asset Management | 2025-06-30 | 460 K | Adage Capital Partners Gp Llc | 2025-06-30 | 6.6 M | Privium Fund Management B.v. | 2025-06-30 | 5 M |
ProQR Fundamentals
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (3.87) % | ||||
| Current Valuation | 48.5 M | ||||
| Shares Outstanding | 105.35 M | ||||
| Shares Owned By Insiders | 18.09 % | ||||
| Shares Owned By Institutions | 51.79 % | ||||
| Number Of Shares Shorted | 1.21 M | ||||
| Price To Earning | (1.97) X | ||||
| Price To Book | 2.30 X | ||||
| Price To Sales | 9.63 X | ||||
| Revenue | 18.91 M | ||||
| Gross Profit | 16.07 M | ||||
| EBITDA | (24.12 M) | ||||
| Net Income | (27.76 M) | ||||
| Cash And Equivalents | 156.4 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 17.22 M | ||||
| Debt To Equity | 0.70 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 0.64 X | ||||
| Cash Flow From Operations | (36.39 M) | ||||
| Short Ratio | 2.16 X | ||||
| Earnings Per Share | (0.48) X | ||||
| Target Price | 8.88 | ||||
| Number Of Employees | 166 | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 154.86 M | ||||
| Total Asset | 167.96 M | ||||
| Retained Earnings | (427.16 M) | ||||
| Working Capital | 114.94 M | ||||
| Current Asset | 97.77 M | ||||
| Current Liabilities | 5.49 M | ||||
| Net Asset | 167.96 M |
About ProQR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProQR Therapeutics BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProQR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProQR Therapeutics BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with ProQR Stock
Moving against ProQR Stock
| 0.58 | ENGN | enGene Holdings Common | PairCorr |
| 0.53 | DSGN | Design Therapeutics | PairCorr |
| 0.52 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.45 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.